What we do
Incanthera is a revenue-generating, UK-based, oncology therapeutics company focusing on drug discovery and development of targeted medicines for the treatment of cancer.
We seek to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading edge discoveries and bring these to commercialisation.
Our current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. Studies on Sol’s permeation across the skin barrier and safety profile on human skin, announced in September 2020, surpassed expectations, strengthening the technology’s commercial potential and valuation. Incanthera introduced Sol to a number of potential commercial partners in 2020, and has now prioritised discussions with two global cosmetic companies to licence Sol’s technology to commercial partners.